- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06187818
Follow up Study of Crocin on Cardiac Function Protection in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy Based on Color Doppler Ultrasound Combined With Myocardial Zymogram
Study of Crocin on Cardiac Function Protection in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy Based on Color Doppler Ultrasound Combined With Myocardial Zymogram
Study Overview
Detailed Description
At present, the commonly used anthracycline antineoplastic drugs in clinic include daunorubicin, doxorubicin, epirubicin, pirarubicin, idabicin, pentarubicin and mitoxantrone, among which doxorubicin is one of the most commonly used antineoplastic drugs. However, anthracyclines have dose dependent and cumulative cardiotoxicity. In patients receiving doxorubicin (DOX) treatment, nearly 10% of patients will have cardiac complications after stopping chemotherapy for nearly 10 years, and its cardiac toxicity may even threaten life, which limits its clinical application.
Crocus sativus glycoside, as the main active ingredient of Crocus sativus L., has a wide range of pharmacological effects, and it has a good effect on cardiovascular system.
Based on the clinical observation and research on the effect of traditional Chinese medicine on the cardiotoxicity of anthracycline drugs, confirm its efficacy, explore the mechanism of cardiac protection, and explore the drug use method of synergism and toxicity reduction of anthracycline drugs in combination with this active ingredient. In this study, 120 patients with breast cancer undergoing neoadjuvant chemotherapy (including anthracycline) were randomly enrolled, and the cardiac baseline assessment was done. The clinical efficacy of crocin in protecting heart function of breast cancer patients undergoing neoadjuvant chemotherapy was evaluated according to clinical symptoms, cardiac color ultrasound, electrocardiogram and myocardial enzyme spectrum, To further verify the clinical application value and social and economic benefits of saffron, the heart protecting active ingredient in saffron, in the aspect of heart protection in neoadjuvant chemotherapy for breast cancer, and further promote the use and broaden the clinical application range of traditional Chinese medicine. Prevention is more important than treatment, which is in line with the national concept of "preventing disease" of traditional Chinese medicine.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250013
- The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital in Shandong Province)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female patients with breast cancer aged ≥ 20 years and ≤ 80 years, with informed consent and meeting the treatment standard of neoadjuvant chemotherapy scheme.
- Patients who plan to receive neoadjuvant chemotherapy based on anthracycline drugs (such as erythromycin, doxorubicin, epirubicin, pyranomycin, idabicin, pentorubicin, and mitoxantrone).
- No treatment for breast cancer before enrollment, such as chemotherapy, targeted therapy and endocrine therapy.
- All patients underwent coarse needle biopsy of breast tumors (axillary lymph node biopsy is required for suspected axillary lymph node metastasis) to determine the status of ER, PR, HER-2, and Ki-67.
- All patients have normal lung function, liver and kidney function.
Exclusion Criteria:
- Cases that do not cooperate and are unwilling to sign informed consent forms.
- Antitumor therapy, hormone replacement therapy and other breast cancer related treatments were performed before enrollment.
- Merge any other malignant tumors.
- Patients with poor image quality in echocardiography.
- Continuous atrial fibrillation and severe arrhythmia affect ultrasound data collection and analysis.
- Patients with active infections, a history of HIV, or chronic hepatitis B or C.
- Patients with abnormal lung function or liver and kidney function.
- Patients with hemorrhagic diseases.
- Patients taking other heart protection traditional Chinese patent medicines and simple preparations.
- Participated in other clinical researchers in the past 3 months.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
experience group 1
Take 4 total glucosides of crocin tablets (Ruiyang Pharmaceutical Co., Ltd.) 3 times a day for 8 days (the day before chemotherapy) during each chemotherapy.Previous history of heart disease.
|
According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected.
During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group [experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period]
|
experience group 2
Take 4 total glucosides of crocin tablets (Ruiyang Pharmaceutical Co., Ltd.) 3 times a day for 8 days (the day before chemotherapy) during each chemotherapy.No previous heart disease.
|
According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected.
During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group [experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period]
|
Control group 1
Did not take crocine tablets during chemotherapy.Previous history of heart disease.
|
|
Control group 2
Did not take crocine tablets during chemotherapy.No previous heart disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac ultrasound LVEF, GLS
Time Frame: December 2024
|
LVEF and GLS levels measured by echocardiography before and after treatment (within and between groups).
|
December 2024
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abnormal rate of electrocardiogram
Time Frame: December 2024
|
Comparison of abnormal electrocardiogram rates before and after treatment (within and between groups).
|
December 2024
|
Overall radial strain of the heart
Time Frame: December 2024
|
Overall radial strain measured by ultrasound before and after treatment (intra group and inter group).
|
December 2024
|
Cardiac asynchrony index
Time Frame: December 2024
|
Cardiac asynchrony index before and after treatment (within and between groups).
|
December 2024
|
myocardial enzymes
Time Frame: December 2024
|
Comparison of myocardial enzyme spectrum results before and after treatment (within and between groups).
|
December 2024
|
Symptoms of cardiac discomfort
Time Frame: December 2024
|
The frequency and duration of chest tightness, chest pain, and palpitations.
|
December 2024
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Guoming Liu, master, The First Affiliated Hospital of Shandong First Medical University (Qianfo Mountain Hospital)
- Principal Investigator: Yonghao Li, master, The First Affiliated Hospital of Shandong First Medical University (Qianfo Mountain Hospital)
- Principal Investigator: Xinlei Zhang, master, The First Affiliated Hospital of Shandong First Medical University (Qianfo Mountain Hospital)
- Principal Investigator: Zhanpeng Zhao, master, The First Affiliated Hospital of Shandong First Medical University (Qianfo Mountain Hospital)
- Principal Investigator: Xuena Zhao, master, The First Affiliated Hospital of Shandong First Medical University (Qianfo Mountain Hospital)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Crocin
-
National Nutrition and Food Technology InstituteVahideh Behrouz; Ali DastkhoshCompleted
-
Qilu Hospital of Shandong UniversityRecruiting
-
Shiraz University of Medical SciencesRecruiting
-
Birjand University of Medical SciencesCompletedHyperglycemia | Metabolic Syndrome | Hypercholesterolemia | HypertriglyceridemiaIran, Islamic Republic of
-
Mashhad University of Medical SciencesUnknownOsteoarthritis, KneeIran, Islamic Republic of
-
Jinnah Postgraduate Medical CentreAga Khan University Hospital, Pakistan; Liaquat National Hospital & Medical...RecruitingParkinson Disease | Neurodegenerative DiseasesPakistan
-
Instituto Universitario de Oftalmobiología Aplicada...EsteveRecruitingContact Lens ComplicationSpain
-
Postgraduate Institute of Medical Education and...CompletedPatent Ductus ArteriosusIndia